Breath Test to Study Children and Teens with Lung, Nerve or Diabetes Conditions
Studies breath samples from young people with lung, nerve or type 1 diabetes conditions.
Plain-language title generated from the registry record
Registry title: Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry in Children and Adolescents
Key facts
- Where
- Basel, SwitzerlandSee the site
Where in Switzerland
- University Children's Hospital Basel (UKBB)Basel, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Children's Hospital Basel
- Trial code
- NCT04461821
- Record updated
- 8 May 2026
- Original description
This study is to investigate breath analysis (breath metabolomics) combined with established bioinformatic tools as a platform for companion diagnostics.Read full original descriptionShow less
Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry in Children and Adolescents (EBECA)
This study is to investigate breath analysis (breath metabolomics) combined with established bioinformatic tools as a platform for companion diagnostics.
Inclusion: Age 0 ≤ 22 years at study entry and signed informed consent; Additional inclusion criteria for respiratory disease population:; Acute disease: - Acute signs for a respiratory disease, indicated by e.g. increased work of breathing (e.g. dyspnea, increased respiratory rate), cough or wheezing; Chronic disease: - Suspected or confirmed chronic airway disease (e.g. asthma); Additional inclusion criteria for neurological disease population:; Acute disease: - Acute presentation or report within 24 hours of any signs of neurological deficit (motor function, sensoneural, or verbal); Chronic disease: - Confirmed chronic neurologic disease (e.g. childhood epilepsy); Additional inclusion criteria for T1D disease population:; Acute disease: - Hyperglycemia and/or pH (venous) <7.3, bicarbonate >10 mmol/L, increased levels of acetone in blood or urine in the context of newly diagnosed or known T1D; Chronic disease: - Confirmed diagnosis of T1D.
Exclusion: Physical or intellectual impairment precluding protocol adherence; Additional exclusion criteria for respiratory disease population:; Known malignancy, active smoker (passive smoke exposure is not an exclusion criterium), known inflammatory diseases (e.g. autoimmune disease) that require medical and/or pharmacological treatment and is associated with an inflammatory response, relevant congenital defects; Additional exclusion criteria for neurological disease population:; Known malignancy, active smoker (passive smoke exposure is not an exclusion criterium), known inflammatory diseases (e.g. autoimmune disease) that require medical and/or pharmacological treatment and is associated with an inflammatory response, relevant congenital defects; Additional exclusion criteria for T1D population:; Known malignancy, active smoker (passive smoke exposure is not an exclusion criterium), relevant congenital defects.